C]glucopyranoside (␣-MG) uptake and its related signal pathways were examined in the primary cultured rabbit renal proximal tubule cells (PTCs). ANG II (Ͼ2 h; Ͼ10 Ϫ9 M) inhibited ␣-MG uptake in a time-and concentration-dependent manner and decreased the protein level of Na ϩ -glucose cotransporters, the expression of which was abrogated by both actinomycin D and cycloheximide exposure. ANG II-induced inhibition of ␣-MG uptake was blocked by losartan, an ANG II type 1 (AT 1) receptor blocker, but not by PD-123319, an ANG II type 2 receptor blocker. ANG II-induced inhibition of ␣-MG uptake was blocked by genistein, herbimycin A [tyrosine kinase (TK) inhibitors], mepacrine, and AACOCF 3 (phospholipase A2 inhibitors), suggesting the role of TK phosphorylation and arachidonic acid (AA). Indeed, ANG II increased AA release, which was blocked by losartan or TK inhibitors. The effects of ANG II on AA release and ␣-MG uptake also were abolished by staurosporine and bisindolylmaleimide I (protein kinase C inhibitors) or PD-98059 (p44/42 MAPK inhibitor), but not SB-203580 (p38 MAPK inhibitor), respectively. Indeed, ANG II increased p44/42 MAPK activity. ANG II-induced activation of p44/42 MAPK was blocked by staurosporine. In conclusion, ANG II inhibited ␣-MG uptake via PKC-MAPK-cPLA 2 signal cascade through the AT1 receptor in the PTCs. angiotensin II; kidney; mitogen activated protein kinase; phospholipase A 2; protein kinase C; sodium ion-glucose cotransporter;
C]glucopyranoside (␣-MG) uptake and its related signal pathways were examined in the primary cultured rabbit renal proximal tubule cells (PTCs). ANG II (Ͼ2 h; Ͼ10 Ϫ9 M) inhibited ␣-MG uptake in a time-and concentration-dependent manner and decreased the protein level of Na ϩ -glucose cotransporters, the expression of which was abrogated by both actinomycin D and cycloheximide exposure. ANG II-induced inhibition of ␣-MG uptake was blocked by losartan, an ANG II type 1 (AT 1) receptor blocker, but not by PD-123319, an ANG II type 2 receptor blocker. ANG II-induced inhibition of ␣-MG uptake was blocked by genistein, herbimycin A [tyrosine kinase (TK) inhibitors], mepacrine, and AACOCF 3 (phospholipase A2 inhibitors), suggesting the role of TK phosphorylation and arachidonic acid (AA). Indeed, ANG II increased AA release, which was blocked by losartan or TK inhibitors. The effects of ANG II on AA release and ␣-MG uptake also were abolished by staurosporine and bisindolylmaleimide I (protein kinase C inhibitors) or PD-98059 (p44/42 MAPK inhibitor), but not SB-203580 (p38 MAPK inhibitor), respectively. Indeed, ANG II increased p44/42 MAPK activity. ANG II-induced activation of p44/42 MAPK was blocked by staurosporine. In conclusion, ANG II inhibited ␣-MG uptake via PKC-MAPK-cPLA 2 signal cascade through the AT1 receptor in the PTCs. angiotensin II; kidney; mitogen activated protein kinase; phospholipase A 2; protein kinase C; sodium ion-glucose cotransporter; ␣-methyl-D- [ 14 C]glucopyranoside A GROWING BODY OF EVIDENCE indicates that ANG II plays an important role in the pathophysiology of renal diseases in humans (31, 50) . Accumulating in vivo evidence also supports the possibility that ANG II may directly cause renal diseases, independent of its blood pressure-elevating effect (7, 31) . The renal proximal tubule can synthesize and secrete ANG II in the lumen, and luminal ANG II levels are 100-to 1,000-fold higher than that found in plasma (47) . The action of ANG II is mediated by two pharmacologically and biochemically distinct classes of receptors, ANG II type 1 (AT 1 ) and ANG II type 2 (AT 2 ). The signaling events elicited in renal cells by ANG II were considered to be divided into separate linear pathways, where intracellular targets of phospholipase A 2 (PLA 2 ) were distinct from those of the phospholipase C (PLC)/protein kinase C (PKC) and tyrosine kinase (TK)/mitogen-activated protein kinase (MAPK)-dependent pathways (21, 44) . Although there is a possibility that these major intracellular signaling cascades do not function independently and are actively engaged in cross-talk, there are still unresolved questions and controversies on the active mechanisms of ANG II. Na ϩ -glucose cotransporters (SGLTs) are expressed in the proximal tubule, where they play a central role in the reabsorption of glucose from the glomerular filtrate. SGLT1 and SGLT2 are expressed in the rabbit renal proximal tubule cells (PTCs; see Ref. 33) . Recent reports including our works suggest that the activity of SGLT is related to the development of diabetic nephropathy (15, 16, 29) . ANG II also has been reported to be involved in the onset of diabetic nephropathy (5) . Our previous studies have demonstrated that ANG II in the PTCs is associated with the pathogenesis of the diabetic nephropathy, since high glucose downregulated ANG II binding because of the increase of ANG II synthesis (35, 36) . However, little is known about the effect of ANG II on ␣-methyl-D-[ 14 C]glucopyranoside (␣-MG) uptake and its related signal pathways in PTCs, although several lines of evidence suggest that ANG II stimulates glucose transport in rat proximal straight tubules (14) or in cultured vascular smooth muscle cells (37) .
When grown in a hormonally defined medium, primary cultured renal PTCs form confluent monolayers of polarized cells, which retain a number of differentiated transport functions typical of the renal PTCs (9) . Included among these transport functions are a probenecid-sensitive p-aminohippurate transport system, an Na ϩ -dependent sugar transport system, and an Na ϩ -dependent P i transport system (9, 17, 52) . The results of studies concerning these membrane transport systems in PTCs are directly comparable to results obtained with original renal tissue (49) . The PTCs respond to a number of hormones known to affect renal PTCs in vivo, including insulin (which inhibits phosphoenolpyruvate carboxykinase activity at physiological concentrations; see Ref. 48 ) and parathyroid hormone (which is stimulatory to adenylate cyclase; see Ref. 43 ). The PTCs lack a similar responsiveness to arginine vasopressin and calcitonin, indicating the PTC culture preparation is highly purified (9) . More recently, we have reported a dose-dependent, biphasic effect of ANG II on Na ϩ uptake by the PTCs, consistent with results obtained with intact renal tissue (18) . Therefore, PTCs in hormonally defined, serum-free culture conditions would be a powerful tool for studying the effect of ANG II on ␣-MG uptake of renal PTCs. Thus we investigated the effect of ANG II on ␣-MG uptake and its related signal cascades in the PTCs.
MATERIALS AND METHODS
Materials. New Zealand White male rabbits (1.5-2.0 kg) were purchased from Dae Han Experimental Animals (Chungju, Korea). Class IV collagenase and soybean trypsin inhibitor were purchased from Life Technologies (Grand Island, NY). ANG II, actinomycin D, cycloheximide, ouabain, mepacrine, AACOCF 3, staurosporine, bisindolylmaleimide I, arachidonic acid (AA), genistein, herbimycin A, indomethacin, econazole, nordihydroguaiaretic acid (NDGA), 12-Otetradecanoylphorbol-13-acetate (TPA), PD-98059, and SB-203580 were obtained from Sigma Chemical (St. Louis, MO). SQ-22536, the Rp diastereomer of cAMP (Rp-cAMP), and protein kinase inhibitor amide- (14) (15) (16) (17) (18) (19) (20) (21) (22) Cell preparation and culture condition. Primary rabbit renal PTC cultures were prepared by the method of Chung et al. (9) . The PTCs were grown in DMEM-Ham's nutrient mixture F-12 (F-12) medium (GIBCO-BRL, Gaithersburg, MD) with 15 mM HEPES and 20 mM sodium bicarbonate (pH 7.4). Immediately before the use of the medium, three growth supplements (5 g/ml insulin, 5 g/ml transferrin, and 5 ϫ 10 Ϫ8 M hydrocortisone) were added. The kidneys of a rabbit were perfused via the renal artery, first with PBS and then with medium containing 0.5% iron oxide. Renal cortical slices were prepared and homogenized. The homogenate was poured first through a 253-m and then an 83-m mesh filter. Tubules and glomeruli on top of the 83-m filter were transferred to sterile medium. Glomeruli (containing iron oxide) were removed with the stirring bar. The remaining tubules were incubated briefly in medium. The tubules were then washed by centrifugation, resuspended in medium containing the three supplements, and transferred to culture dishes. Medium was changed 1 day after plating and every 2 days thereafter. Primary cultured rabbit kidney PTCs were maintained in a 37°C, 5% CO 2 humidified environment in a serum-free basal medium supplemented with three growth supplements. PTCs were confluent and quiescent for 48 h, and then experiments were conducted.
␣-MG uptake. ␣-MG uptake experiments were conducted as described by the method of Sakhrani et al. (38) . To study ␣-MG uptake, the culture medium was removed by aspiration, and monolayers were washed gently two times with the uptake buffer (136 mM NaCl, 5.4 mM KCl, 0.41 mM MgSO 4, 1.3 mM CaCl2, 0.44 mM Na2HPO4, 0.44 mM KH2PO4, 5 mM HEPES, 2 mM glutamine, and 0.5 g/ml BSA, pH 7.4). After the washing procedure, the monolayers were incubated at 37°C for 30 min in an uptake buffer that contained 0.5 mM ␣-MG and ␣-[
14 C]MG (0.5 Ci/ml). At the end of the incubation period, the monolayers were again washed three times with ice-cold uptake buffer, and the cells were solubilized in 1 ml of 0.1% SDS. To determine the ␣-[
14 C]MG incorporated intracellulary, 900 l of each sample were removed and counted in a liquid scintillation counter (LS 6500; Beckman Instruments, Fullerton, CA). The remainder of each sample was used for protein determination (4). 3-O-[
14 C]MG uptake was conducted using 3-O-
The next steps were conducted as described in ␣-MG uptake. Fructose, Larginine, and alanine uptake was conducted according to the method 3 H]AA/ml and the three growth supplements. The monolayers were then washed three times with DMEM-F-12 (pH 7.4) and incubated (at 37°C) for 1 h in uptake buffer containing the specified agents at appropriate concentrations. At the end of the incubation period, the incubation medium was removed by aspiration and transferred to ice-cold tubes containing 100 l of 55 mM EGTA (final concentration, 5 mM each). The uptake buffer was then centrifuged at 12,000 g to eliminate cell debris. To determine the level of radioactivity in the supernatant, the samples were placed in scintillation vials containing scintillation fluid, and the radioactivity was counted using a liquid scintillation counter. The cells that remained attached to the plate were scraped into 1 ml of 0.1% SDS. The 900 l of the resulting cell lysate were used for scintillation counting. The remaining 100 l of the cell lysate were used for protein determinations. For each condition, the quantity of [ 3 H]AA that had been released (determined as described above) was first standardized with respect to protein. Subsequently, this standardized level of released [ 3 H]AA was compared by the percentage to the total level of [ 3 H]AA that had been incorporated in the cells at the beginning of the incubation period (the total released radioactivity plus the total cellassociated radioactivity at the end of the stimulation period).
Membrane preparation for SGLTs blotting. Medium of confluent PTCs was exchanged 1 day before the experiment. The medium was then removed, and the cells were washed two times with ice-cold PBS, scraped, harvested by microcentrifugation, and resuspended in buffer A [137 mM NaCl, 8.1 mM Na 2HPO4, 2.7 mM KCl, 1.5 mM KH2PO4, 2.5 mM EDTA, 1 mM dithiothreitol, 0.1 mM PMSF, and 10 g/ml leupeptin (pH 7.5)]. The resuspended cells were then mechan- ically lysed on ice by trituration with a 21.1-gauge needle. The lysates were first centrifuged at 1,000 g for 10 min at 4°C. The supernatants were centrifuged at 100,000 g for 1 h at 4°C to prepare cytosolic and total particulate fractions. The particulate fractions, which contained the membrane fraction, were washed two times and resuspended in buffer A containing 1% (vol/vol) Triton X-100. The protein in each fraction was quantified with a Bradford (4) procedure.
Western blot analysis. Cell homogenates (20 g protein) were separated on 10% SDS-PAGE and transferred to nitrocellulose paper. Blots were then washed with H2O, blocked with 5% skimmed milk powder in 10 mM Tris⅐HCl (pH 7.6), 150 mM NaCl, and 0.05% Tween 20 for 1 h, and incubated with the appropriate primary antibody at dilutions recommended by the supplier. Next, the membrane was washed, and primary antibodies were detected with goat anti-rabbit-IgG conjugated to horseradish peroxidase, and the bands were visualized with enhanced chemiluminescence (Amersham Pharmacia Biotech)
125 I-labeled ANG II binding. The ANG II binding assays were performed as described by Becker and Harris (3) . To summarize, after the incubation of PTCs with losartan or PD-123319 at different dosages (10 Ϫ9 , 10 Ϫ7 , and 10 Ϫ5 M) for 30 min, confluent monolayers of PTCs were washed two times with ice-cold PBS containing 0.1% albumin (PBS-A), and cells were incubated in PBS-A, supplemented with 125 I-labeled [Sar 1 ,Ile 8 ]ANG II (0.1 nM) at 4°C for 4 h, followed by three washes with the same ice-cold PBS-A. After solubilization in 0.5 N NaOH (1 ml), 900 l of each sample were transferred to a scintillation tube and counted in a gamma counter (Wizard 1470; Wallac, Turku, Finland). The remainder of each sample was used for protein determination by the Bradford (6) method.
cAMP assay. The confluent PTCs were then incubated with a different dosage of ANG II (0 to 10 Ϫ7 M) for 8 h at 37°C in a humidified, 5% CO 2-95% air environment. Subsequently, samples were prepared for intracellular cAMP determinations by homogenization in serum-free media containing 4 mM EDTA using a Polytron PT 1200, followed by a 5-min incubation at 100°C. After centrifugation at 890 g for 5 min, the supernatants were transferred to new tubes and stored at 4°. These samples were used for cAMP assays, using a Statistical analysis. Results were expressed as means Ϯ SE. The difference between two mean values was analyzed by the nonparametric Wilcoxon sign test or ANOVA. The difference was considered statistically significant at P Ͻ 0.05.
RESULTS

Effect of ANG II on ␣-MG uptake.
To determine whether ANG II affects ␣-MG uptake in a time-dependent manner, PTCs were exposed to 10 Ϫ7 M ANG II for various time intervals (Fig. 1A) . ANG II significantly inhibited ␣-MG uptake over 2 h and exhibited a maximal inhibitory effect between 8 and 12 h. To determine the concentration dependency of ANG II on ␣-MG uptake, PTCs were exposed to various concentrations of ANG II for 8 h. ANG II above 10 Ϫ9 M inhibited ␣-MG uptake, and maximum inhibition of ␣-MG uptake was observed at 10 Ϫ7 M ANG II (Fig. 1B) . To validate the above-mentioned effect of ANG II on ␣-MG uptake in the PTCs, we additionally examined the effect of ANG II on Na ϩ transport. As shown in Fig. 1C , ANG II has biphasic effects on Na ϩ uptake; a low concentration of ANG II (10 Ϫ11 M) stimulates Na ϩ uptake, whereas a high concentration of ANG II (Ն10 Ϫ9 M) inhibits it. On the other hand, in the experiments to examine specificity of the ANG II on ␣-MG uptake, ANG II On the other hand, ANG II-induced inhibition of ␣-MG uptake may be, in part, mediated by the inhibition of Na ϩ -K ϩ -ATPase, since ouabain in the absence of ANG II inhibited ␣-MG uptake (Fig. 2) .
To determine whether RNA and protein synthesis are involved in the ANG II-induced inhibition of ␣-MG uptake, PTCs were treated with actinomycin D (a transcription inhibitor, 10 Ϫ7 M) or cycloheximide (a translation inhibitor, 4 ϫ 10 Ϫ5 M) for 30 min before the treatment of ANG II. Actinomysin D and cycloheximide blocked ANG II-induced inhibition of ␣-MG uptake (Fig. 3) . In experiments to determine effects of ANG II on the protein expression level of SGLTs, ANG II (10 Ϫ7 M, 8 h) significantly decreased the SGLT1 and SGLT2 protein levels. Western blots probed with anti-␤-actin showed no differences in the loading protein levels. Consistent with the ␣-MG uptake result, actinomysin D and cycloheximide blocked the ANG II-induced decrease of both SGLT1 and SGLT2 protein expression (Fig. 4) . Densitometric analysis demonstrated that 8 h of exposure to 10 Ϫ7 M ANG II significantly decreased SGLT1 or SGLT2 band density to 73 Ϯ 8 and 49 Ϯ 25% of control, respectively.
To determine whether the inhibition of ␣-MG uptake induced by ANG II is mediated by AT receptors, PTCs were treated with losartan or PD-123319 in a dose-dependent manner before [ (Fig. 5B) .
Role of AA in ANG II-induced inhibition of ␣-MG uptake. To determine whether phosphorylation of TK is involved in the effect of ANG II on ␣-MG uptake, PTCs were treated with genistein or herbimycin A (10 Ϫ6 M, TK inhibitors) before the treatment of ANG II (10 Ϫ7 M). Genistein and herbimycin A completely blocked ANG II-induced inhibition of ␣-MG uptake (Fig. 6) . We also investigated the relation of the PLA 2 signal pathway in ANG II-induced inhibition of ␣-MG uptake. Thus PTCs were treated with mepacrine or AACOCF 3 (10 Ϫ6 M), PLA 2 inhibitors, for 30 min before the treatment of ANG II (10 Ϫ7 M). Mepacrine and AACOCF 3 blocked ANG IIinduced inhibition of ␣-MG uptake, suggesting that AA is involved in ANG II-induced inhibition of ␣-MG uptake (Fig.  7A) . Indeed AA inhibits ␣-MG uptake. Furthermore, indomethacin (a cyclooxygenase inhibitor) and econazole (a cytochrome P-450 epoxygenase inhibitor), but not NDGA (a lipoxygenase inhibitor, 10 Ϫ6 M), abolished ANG II-induced inhibition of ␣-MG uptake (Fig. 7B) . PGE 2 (Ͼ10 Ϫ9 M), one of cyclooxygenase metabolites, and 5,6-epoxy-eicosatrienoic acid (EET, Ͼ10 Ϫ8 M), one of the cytochrome P-450 metabolites, inhibited ␣-MG uptake (Fig. 7B, inset) . ANG II (10 Ϫ7 M, 1 h) increased AA release (Fig. 8 ). Mepacrine and AACOCF 3 prevented the ANG II-induced increase of AA release (data not shown). When PTCs were treated with losartan (an AT 1 receptor antagonist), genistein, or herbimycin A (TK inhibitors; 10 Ϫ6 M) before the treatment of ANG II, AA release induced by ANG II was also blocked. AA, PGE 2 , or 5,6-EET inhibits ␣-MG uptake in the presence of TK inhibitors (Fig. 8, inset) or PLA 2 inhibitors (data not shown).
Involvement of cAMP/PKC in ANG II-induced increase of AA release and inhibition of ␣-MG uptake. To identify the role of the cAMP signal pathway in the ANG II-induced inhibition of ␣-MG uptake, PTCs were treated with SQ-22536 (10 Ϫ6 M, an adenylate cyclase inhibitor), Rp-cAMP (10 Ϫ5 M, cAMP analog), and myristoylated PKI amide-(14-22) (10 Ϫ5 M, a protein kinase A inhibitor) before the treatment of ANG II. SQ-22536, Rp-cAMP, or PKI did not block the ANG IIinduced inhibition of ␣-MG uptake (Fig. 9A) . Indeed, ANG II did not affect cAMP content (Fig. 9B) . This result suggests that cAMP pathways are not involved in the effect of ANG II on ␣-MG uptake. To examine the involvement of PKC on the ANG II-induced increase of AA, PTCs were treated with TPA (100 ng/ml, a PKC activator) alone or in combination with ANG II. TPA increased [ 3 H]AA release by 68 Ϯ 9% compared with control, suggesting the possibility that PKC is involved in the ANG II-induced increase of [ 3 H]AA release (Fig. 10) . TPA also inhibits ␣-MG uptake by 72 Ϯ 11% compared with control. Thus, to investigate the involvement of PKC in the effect of ANG II, PTCs were treated with staurosporine (10 Ϫ7 M) or bisindolylmaleimide I (10 Ϫ6 M) (PKC inhibitors) for 30 min before the treatment of ANG II. Staurosporine and bisindolylmaleimide I completely blocked the ANG II-induced increase of [ 3 H]AA release and inhibition of ␣-MG uptake (Fig. 10) . These results indicate that PKC is a more upstream regulator than PLA 2 in the ANG II-induced increase of [ 3 H]AA release and inhibition of ␣-MG uptake. In addition, we examined whether TPA could inhibit ␣-MG uptake in the presence of TK inhibitors. TPA-induced inhibition of ␣-MG uptake was not blocked by genistein and herbimycin A (Fig.  10, inset) . These results indicate that the inhibitory effect of ANG II and ␣-MG uptake via the PKC signaling pathway is downstream of TK phosphorylation. (Fig. 11) . TK inhibitor or p44/42 MAPK inhibitor does not abolish the inhibition of ␣-MG uptake induced by AA (data not shown). It suggests that TK or MAPK is upstream of the AA signal pathway. These results suggest that p44/42 MAPK activation is needed to have an inhibitory effect of ␣-MG uptake by ANG II. Indeed, ANG II rapidly induced p44/42 MAPK activation over 5 min (Fig. 12A ). There was a sustained activation of p44/42 MAPK by 2 h. In addition, ANG II-induced activation of p44/42 MAPK was blocked by PKC inhibitor (Fig. 12B) .
DISCUSSION
First, this study demonstrated that ANG II inhibited ␣-MG uptake via TK-PKC-MAPK-cytosolic (c) PLA 2 signal cascades in the PTCs. We previously reported that the treatment of ANG II for 4 h has a biphasic effect on Na ϩ transport in the PTCs; a picomolar range of ANG II stimulates Na ϩ transport, whereas a micromolar range of ANG II inhibits it (18) . However, there is no biphasic effect of ANG II on SGLT, indicating that ANG II differently regulates ␣-MG uptake, unlike Na ϩ transport. Glucose in the lumen is reabsorbed by SGLTs in the brush-border membrane, accumulated within the cells, and transported out of the cell across the basolateral membrane by a facilitated sugar transporter (33) . In the present study, ANG II did not affect 3-O-MG, fructose, L-arginine, and alanine transporter, which is expressed in the renal proximal tubule (12, 41) . It suggests that ANG II specifically regulates SGLTs.
The concentration of ANG II used in this study has an important pathophysiological significance in the regulation of renal proximal tubule functions, since 1) the concentration of ANG II in the kidney is 1,000 times higher than the normal range of plasma (39) , 2) plasma ANG II concentrations have been estimated to range from 10 Ϫ11 to 3 ϫ 10 Ϫ9 M (under conditions of sodium depletion; see Ref. 32) , and 3) the concentration of ANG II is increased in diabetic animals (46) . Recently, we have demonstrated that high glucose inhibited ␣-MG uptake in PTCs (15, 16) . Others have demonstrated that high glucose resulted in a reduction of the expression and activity of SGLTs (23) and that SGLT activity was decreased in brushborder membrane vesicles of diabetic rats (19) . In the present study, we also found that ANG II reduces the expression of SGLT1 and SGLT2 and ␣-MG uptake. Our results and those of others suggest that ANG II is involved in the high glucoseinduced inhibition of ␣-MG uptake through increasing of ANG II by high glucose (15, 16) . Consistent with our present and previous results (18), Burns and colleague (6) (21, 44) . In the present study, TK activation is required for the action of ANG II. ANG II via AT 1 receptor rapidly activates TK in the rabbit PTCs (22) . Our present studies have shown that the effects of ANG II on ␣-MG uptake are mediated by cPLA 2 and the metabolites of cPLA 2 . This result is supported by the reports that the proximal tubule is rich in cytochrome P-450 enzyme activity (13) and that cyclooxygenase inhibitor blocked the effect of ANG II and ANG II increased PGE 2 synthesis in rabbit PTCs although the level of cyclooxygenase in proximal tubules is minimal (1, 28, 18 ). Of interest, in the present study, the treatment of 5,6-EET and PGE 2 , metabolites of AA, for 8 h mimicked the effect of ANG II, but they did not affect ␣-MG uptake in the short time of incubation (30 min; unpublished data). This result suggests that metabolites of AA may be involved in the reduction of SGLT expression, resulting in the decrease of ␣-MG uptake of PTCs exposed to ANG II.
The present results also demonstrated that ANG II-induced AA release is involved in PKC in PTCs. Several investigators have demonstrated that PKC inhibitors block AA or PGE 2 release induced by ANG II in rat vascular smooth muscle cells (27) or aortic endothelial cells (30) , and rabbit renal SGLT1 has a PKCbinding site and is modulated by PKC (20) . In addition, ANG II elicited translocation of PKC-␣ in the PTCs (8) and stimulated Na (41, 45) . However, some studies suggested that ANG II-induced p44/42 MAPK activation was PKC independent (25, 26) . Our results show that PKC regulates the activation of p44/42 MAPK induced by ANG II, indicating the flow of ANG II-PKC-p44/42 MAPK. This is the first report, to our knowledge, that PKC, MAPK, and AA are responsible for the regulation of SGLT by ANG II in PTCs. These results suggest that alterations of these highly regulated SGLTs by ANG II may be a pivotal role in pathogenesis of renal disease, such as diabetic nephropathy, which increased the intrarenal ANG II level (40, 54) .
Taken together, we illustrated a hypothetical model of the signaling mechanisms involved in mediating the ANG IIinduced inhibition of SGLT (Fig. 13) . In summary, ANG II activates AT 1 receptor and stimulates PKC, which triggers p44/42 MAPK activation. Subsequently, p44/42 MAPK activation induces the release of [ 3 H]AA, which is metabolized to 5,6-EET or PGE 2 by cyclooxygenase and cytochrome P-450. These molecules may induce the decrease of SGLTs protein expression, which is involved in inhibition of SGLT activity of renal PTCs.
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